Skip to main content
. 2022 Mar 6;14(3):549. doi: 10.3390/v14030549

Figure 2.

Figure 2

EK1-C16-mediated inhibition of SARS-CoV-2 infection. (A) EK1-C16-mediated inhibition of SARS-CoV-2 D614G S-meditated cell–cell fusion. (B) EK1-C16-mediated inhibition of SARS-CoV-2 WT (Wuhan-Hu-1) PsV infection. (C) Cytotoxicity of EK1-C16 to RD cells was tested by using a CCK-8 assay. (D) EK1-C16-mediated inhibition of authentic SARS-CoV-2 WT (nCoV-SH01) infection. Samples were tested in triplicate, and the experiment was repeated at least twice.